Health Economics›Neuroblastoma›High-risk induction

High-risk induction

Neuroblastoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
N5/N6 Variant #01 Partial	—	R 23 752	21d	—	—	~3	~R 71 256 indirect	—
COJEC Variant #01	—	R 5 343	10d	—	—	~8	~R 16 811 indirect	—

2 of 2 regimens shown